Since lipogenic gene expression is associated with tumor aggressiveness, targeting the enzymes such as FASN, SCD1, ACC1, and the transcription factor that regulates lipogenic gene expression (sterol-regulatory element-binding protein-1c (SREBP1c)) with lipogenic inhibitors might be of therapeutic importance. The gene discussed is FASN; the disease is neoplasm.